Lessons Learned on Preparing to Weather the Inevitable Challenges in Biotech

By Joshua Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC

By all accounts, 2022 did not start according to plan for the biotech industry. The U.S. economy and growth stocks struggled with the broader biotech index down by more than 45 percent through the first half of the year.

Throughout my career in biotech, I have learned that this industry is filled with twists and turns and, at times, setbacks. However, there are some key strategies that you can employ to best prepare for uncertainty in our business. Building an early position of strength is key to overcoming challenges that others may find…